Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE2
Study Classification
INTERVENTIONAL
Study Start Date
2015-01-01
Study Completion Date
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The proposed project aims to increase accessibility of exposure therapy, an evidence based treatment for social anxiety disorder, by adapting a therapist-assisted computer-based program to be delivered in a self-guided manner on an iPad. A significant problem with self-guided treatment delivered via computer is compliance. The vast majority of users do not complete treatment, so achieving therapeutic benefit as quickly as possible is essential. D-cycloserine is a drug found to augment response to therapist-guided exposure therapy for anxiety disorders, but has never been tested with self-guided exposure. This study uses a randomized, double-blind methodology to compare D-cycloserine (50 mg; DCS) to placebo in combination with self-guided virtual reality exposure therapy (VRE) delivered via iPad to treat social anxiety disorder. The proposed study tests the hypothesis that patients who receive DCS in combination with the self-guided VRE will show more improvement than those who receive placebo in combination with VRE. Outcome measures include self-reported symptoms of social anxiety, behavioral avoidance, and diagnostic remission. Participants (N=34) are adults with a primary diagnosis of social anxiety disorder. Participants will complete a structured diagnostic interview, standardized self-report measures of social anxiety, and a behavioral avoidance task (i.e., giving a speech) and will be assessed at pre-treatment, at post-treatment and at 3 month follow-up. Hierarchical linear regression and chi-square analyses will be used to test differences between those randomized to DCS versus placebo on the following outcomes: post-treatment scores of self-reported social phobia symptoms, willingness to and anxiety while giving a speech at post-treatment, and diagnostic remission at 3 month follow-up. The proposed project combines technological advances with translational research to develop an innovative and accessible treatment for those with social anxiety disorder. The pilot data generated from this study will be appealing to a variety of funding agencies, including the National Institute of Mental Health's call for exploratory clinical trials of novel interventions for mental illnesses, the Patient-Centered Outcomes Research Institute's call for effectiveness studies aimed to overcome barriers to treatment, and the National Science Foundation's call for innovation-technology translation research.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Virtual Reality Exposure Therapy for the Treatment of Social Phobia
NCT02379949
Social Anxiety Disorder
COMPLETED
NA
Pilot Study of Virtual Reality for Providing Exposure Therapy to Children
NCT03208348
Generalized Anxiety Disorder
COMPLETED
NA
Telemedicine-Based Virtual Reality Clinic for the Treatment of Phobias
NCT06302868
Arachnophobia
Cynophobia
Ophidiophobia
RECRUITING
NA
Using Virtual Reality in Exposure-Based Treatment for Social Anxiety in Youth
NCT03135990
Social Anxiety
Social Anxiety Disorder
Social Anxiety Disorder of Childhood
TERMINATED
NA
Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and OCD
NCT02713516
Anxiety
Obsessive Compulsive Disorder
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Social Anxiety Disorder (social phobia) is the most common psychiatric disorder in the US. It negatively impacts health-related quality of life, educational and economic achievement, and it leads to attempted suicide in as many as 21% of affected individuals. A critical barrier to progress in reducing the negative impact of this disorder is that 75-92% of sufferers do not receive treatment. Social phobia self-help programs delivered via computer are designed to increase access to treatment and can be effective. Compliance and completion rates of such programs are, however, quite poor, greatly limiting their impact and accessibility. Furthermore, self-help programs for social phobia do not directly administer a critical component of treatment - exposure therapy. The direct administration of self-guided exposure therapy, using virtual reality is an innovation that would increase the accessibility and impact of computer delivered treatment.
Exposure therapy is based on well-researched fear extinction learning paradigms, where individuals confront what they fear in a therapeutic manner and learn that the feared outcome will not occur. Ressler et al's groundbreaking translational research showed that D-cycolserine (DCS), an analogue of D-alanine and a partial agonist at the NMDA receptor, facilitates the process of fear extinction. DCS is different from other pharmacological agents used to treat social phobia which are prescribed chronically (daily) over a period of months or years to maintain a therapeutic dose; one pill of DCS is taken immediately before exposure therapy sessions. This work sparked a flurry of research showing that DCS augments exposure therapy for a variety of anxiety disorders; people who take DCS show benefit from therapist-assisted exposure therapy more quickly than those who take placebo. Two randomized double-blind, placebo-controlled studies of social phobia conclude that the combination of DCS and therapist-assisted exposure therapy improves treatment response when participants complete fewer exposure sessions. The ability of DCS to speed up the response to exposure therapy is especially valuable for sufferers using self-guided treatment, because they are not generally compliant with the full exposure protocol. The combination of DCS and self-guided exposure therapy would increase access to effective treatment. The use of DCS with self-guided exposure, however, has never been tested.
Specific Aims
1. Adapt an existing computer program to deliver self-guided VRE for social phobia via iPad, and
2. Test the comparative efficacy of DCS vs placebo plus self-guided VRE.
Hypothesis: Participants who receive self-guided VRE plus DCS will show less self-reported social anxiety and less avoidance during a laboratory based behavioral test following a 5-week intervention than those who received self-guided VRE plus placebo.
The investigators seek to shift current clinical practice in the treatment of social phobia so that more people with the disorder receive exposure therapy. The investigators will improve access to evidence-based treatment for social phobia with delivery of exposure via a computer - a modality that capitalizes on the fact that people with severe social phobia spend extensive hours on the computer; exposure therapy can come to people with social phobia "where they are." The investigators also will be the first to test the delivery of exposure therapy on an iPad. The study design improves the approach of existing research on computer-delivered programs for social phobia by testing how treatment affects real behavior - existing research has relied exclusively on self-report measures and assessment of diagnostic status. No studies have assessed actual behavior - either in the lab or in the real-world. This study will improve scientific knowledge by answering the question of whether or not DCS augments self-guided exposure therapy. The combination of a self-help program with DCS addresses many of the obstacles to treatment with therapist-guided exposure therapy. For example, there are not enough mental health providers trained in exposure therapy. Furthermore, social anxiety disorder is characterized by the fear and avoidance of social situations, and psychotherapy is inherently a social encounter. The effective combination of DCS and self-guided virtual reality exposure is an avenue for treatment to any sufferer with access to a computer and a prescribing physician. When the proposed aims are achieved, an innovative treatment will exist that did not before - self-guided VRE delivered via computer.
The investigators have developed and tested a self-help program delivered via computer, with minimal therapist support. The self-help program was tested in a small (N=10) uncontrolled trial of 8 sessions, and results showed decreases in scores on standardized self-report measures of social anxiety from pre- to post-treatment and follow-up. Large effect sizes were observed at post-treatment (d = 1.22-1.53) and follow-up (d = 1.41 - 2.39).
Using standardized measures of software usability, participants described the program as easy-to-use, including a participant who had never before used a computer. Since this study, the program has been updated with new virtual environments, as well as shortening the treatment down. The proposed project will adapt an existing program for delivery via a tablet and to collect data via the computer.
Finally, the investigative team completed a double-blind, placebo controlled trial that tested the combination of DCS vs placebo combined with therapist-guided VRE for specific phobia.
Thus, the investigative team is well-positioned to complete the specific aims of adapting a computer program that delivers self-guided exposure therapy for social phobia via a tablet and testing following hypothesis: Participants who receive self-guided exposure therapy plus DCS will show less self-reported social anxiety and less avoidance during a laboratory based behavioral test following a 5-week intervention than those who received self-guided exposure therapy plus placebo.
Exposure therapy is based on well-researched fear extinction learning paradigms, where individuals confront what they fear in a therapeutic manner and learn that the feared outcome will not occur. Ressler et al's groundbreaking translational research showed that D-cycolserine (DCS), an analogue of D-alanine and a partial agonist at the NMDA receptor, facilitates the process of fear extinction. DCS is different from other pharmacological agents used to treat social phobia which are prescribed chronically (daily) over a period of months or years to maintain a therapeutic dose; one pill of DCS is taken immediately before exposure therapy sessions. This work sparked a flurry of research showing that DCS augments exposure therapy for a variety of anxiety disorders; people who take DCS show benefit from therapist-assisted exposure therapy more quickly than those who take placebo. Two randomized double-blind, placebo-controlled studies of social phobia conclude that the combination of DCS and therapist-assisted exposure therapy improves treatment response when participants complete fewer exposure sessions. The ability of DCS to speed up the response to exposure therapy is especially valuable for sufferers using self-guided treatment, because they are not generally compliant with the full exposure protocol. The combination of DCS and self-guided exposure therapy would increase access to effective treatment. The use of DCS with self-guided exposure, however, has never been tested.
Specific Aims
1. Adapt an existing computer program to deliver self-guided VRE for social phobia via iPad, and
2. Test the comparative efficacy of DCS vs placebo plus self-guided VRE.
Hypothesis: Participants who receive self-guided VRE plus DCS will show less self-reported social anxiety and less avoidance during a laboratory based behavioral test following a 5-week intervention than those who received self-guided VRE plus placebo.
The investigators seek to shift current clinical practice in the treatment of social phobia so that more people with the disorder receive exposure therapy. The investigators will improve access to evidence-based treatment for social phobia with delivery of exposure via a computer - a modality that capitalizes on the fact that people with severe social phobia spend extensive hours on the computer; exposure therapy can come to people with social phobia "where they are." The investigators also will be the first to test the delivery of exposure therapy on an iPad. The study design improves the approach of existing research on computer-delivered programs for social phobia by testing how treatment affects real behavior - existing research has relied exclusively on self-report measures and assessment of diagnostic status. No studies have assessed actual behavior - either in the lab or in the real-world. This study will improve scientific knowledge by answering the question of whether or not DCS augments self-guided exposure therapy. The combination of a self-help program with DCS addresses many of the obstacles to treatment with therapist-guided exposure therapy. For example, there are not enough mental health providers trained in exposure therapy. Furthermore, social anxiety disorder is characterized by the fear and avoidance of social situations, and psychotherapy is inherently a social encounter. The effective combination of DCS and self-guided virtual reality exposure is an avenue for treatment to any sufferer with access to a computer and a prescribing physician. When the proposed aims are achieved, an innovative treatment will exist that did not before - self-guided VRE delivered via computer.
The investigators have developed and tested a self-help program delivered via computer, with minimal therapist support. The self-help program was tested in a small (N=10) uncontrolled trial of 8 sessions, and results showed decreases in scores on standardized self-report measures of social anxiety from pre- to post-treatment and follow-up. Large effect sizes were observed at post-treatment (d = 1.22-1.53) and follow-up (d = 1.41 - 2.39).
Using standardized measures of software usability, participants described the program as easy-to-use, including a participant who had never before used a computer. Since this study, the program has been updated with new virtual environments, as well as shortening the treatment down. The proposed project will adapt an existing program for delivery via a tablet and to collect data via the computer.
Finally, the investigative team completed a double-blind, placebo controlled trial that tested the combination of DCS vs placebo combined with therapist-guided VRE for specific phobia.
Thus, the investigative team is well-positioned to complete the specific aims of adapting a computer program that delivers self-guided exposure therapy for social phobia via a tablet and testing following hypothesis: Participants who receive self-guided exposure therapy plus DCS will show less self-reported social anxiety and less avoidance during a laboratory based behavioral test following a 5-week intervention than those who received self-guided exposure therapy plus placebo.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Social Anxiety Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DCS
Participants will receive 50mg of Seromycin (aka D-cycloserine) in conjunction with virtual reality exposure therapy once a week for 4 weeks.
Group Type
EXPERIMENTAL
Seromycin
Intervention Type
DRUG
Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
Virtual Reality Exposure Therapy
Intervention Type
BEHAVIORAL
Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
Placebo
Participants will receive a placebo in conjunction with virtual reality exposure therapy once a week for 4 weeks.
Group Type
PLACEBO_COMPARATOR
Virtual Reality Exposure Therapy
Intervention Type
BEHAVIORAL
Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
Placebo
Intervention Type
DRUG
Administered in pill form.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Seromycin
Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
Intervention Type
DRUG
Virtual Reality Exposure Therapy
Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
Intervention Type
BEHAVIORAL
Placebo
Administered in pill form.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
D-cycloserine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Understand and provide written informed consent prior to conduct of any study procedures.
* Be able to communicate in English with study personnel
* Be able to manipulate the computer interface to interact with the program
* If female, must have a negative pregnancy test prior to treatment and be maintained on an acceptable method of birth control during treatment
* If using psychotropic medication, stable on medication and dosage for 3 months
* Be able to communicate in English with study personnel
* Be able to manipulate the computer interface to interact with the program
* If female, must have a negative pregnancy test prior to treatment and be maintained on an acceptable method of birth control during treatment
* If using psychotropic medication, stable on medication and dosage for 3 months
Exclusion Criteria
* Participation in clinical trial within the past 12 months or treatment with DCS in a previous study
* History of mania, schizophrenia, or other psychoses
* Any unstable medical condition; Seizure disorders, with the exception of a childhood history of isolated, non-recurrent febrile seizures
* Current or past substance (except nicotine, caffeine) or alcohol dependence based on DSM-V criteria within six months prior to screening
* Liebowitz Social Anxiety Scale (LSAS) score of \< 50 at baseline
* History of mania, schizophrenia, or other psychoses
* Any unstable medical condition; Seizure disorders, with the exception of a childhood history of isolated, non-recurrent febrile seizures
* Current or past substance (except nicotine, caffeine) or alcohol dependence based on DSM-V criteria within six months prior to screening
* Liebowitz Social Anxiety Scale (LSAS) score of \< 50 at baseline
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emory University
OTHER
Sponsor Role
collaborator
Georgia State University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Page Anderson
Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Page Anderson, PhD
Role: PRINCIPAL_INVESTIGATOR
Georgia State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Georgia State University
Atlanta, Georgia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Del Bene D, Liebowitz MR. Functional impairment in social phobia. J Clin Psychiatry. 1994 Aug;55(8):322-31.
Reference Type
BACKGROUND
Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992 Apr;49(4):282-8. doi: 10.1001/archpsyc.1992.01820040034004.
Reference Type
BACKGROUND
Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. PLoS One. 2010 Oct 13;5(10):e13196. doi: 10.1371/journal.pone.0013196.
Reference Type
BACKGROUND
Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: randomised controlled trial. BMJ. 2004 Jan 31;328(7434):265. doi: 10.1136/bmj.37945.566632.EE. Epub 2004 Jan 23.
Reference Type
BACKGROUND
Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007 Mar 6;146(5):317-25. doi: 10.7326/0003-4819-146-5-200703060-00004.
Reference Type
BACKGROUND
Hofmann SG, Sawyer AT, Asnaani A. D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update. Curr Pharm Des. 2012;18(35):5659-62. doi: 10.2174/138161212803530916.
Reference Type
BACKGROUND
Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar;63(3):298-304. doi: 10.1001/archpsyc.63.3.298.
Reference Type
BACKGROUND
Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008 Mar 15;63(6):544-9. doi: 10.1016/j.biopsych.2007.11.011. Epub 2008 Jan 7.
Reference Type
BACKGROUND
Caplan SE. Relations among loneliness, social anxiety, and problematic Internet use. Cyberpsychol Behav. 2007 Apr;10(2):234-42. doi: 10.1089/cpb.2006.9963.
Reference Type
BACKGROUND
Anderson PL, Price M, Edwards SM, Obasaju MA, Schmertz SK, Zimand E, Calamaras MR. Virtual reality exposure therapy for social anxiety disorder: a randomized controlled trial. J Consult Clin Psychol. 2013 Oct;81(5):751-60. doi: 10.1037/a0033559. Epub 2013 Jun 24.
Reference Type
BACKGROUND
Anderson P, Zimand E, Schmertz SK, Ferrer M. Usability and utility of a computerized cognitive-behavioral self-help program for public speaking anxiety. Cognitive and Behavioral Practice 14(2):198-207. 2007.
Reference Type
BACKGROUND
Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004 Nov;61(11):1136-44. doi: 10.1001/archpsyc.61.11.1136.
Reference Type
BACKGROUND
Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med. 1999 Jan;29(1):199-212. doi: 10.1017/s0033291798007879.
Reference Type
BACKGROUND
Safren SA, Heimberg RG, Horner KJ, Juster HR, Schneier FR, Liebowitz MR. Factor structure of social fears: The Liebowitz Social Anxiety Scale. J Anxiety Disord. 1999 May-Jun;13(3):253-70. doi: 10.1016/s0887-6185(99)00003-1.
Reference Type
BACKGROUND
Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther. 1998 Apr;36(4):455-70. doi: 10.1016/s0005-7967(97)10031-6.
Reference Type
BACKGROUND
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999 Nov 10;282(18):1737-44. doi: 10.1001/jama.282.18.1737.
Reference Type
BACKGROUND
Kadouri A, Corruble E, Falissard B. The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry. 2007 Feb 6;7:7. doi: 10.1186/1471-244X-7-7.
Reference Type
BACKGROUND
Turner SM, Beidel DC, Cooley MR, Woody SR, Messer SC. A multicomponent behavioral treatment for social phobia: social effectiveness therapy. Behav Res Ther. 1994 May;32(4):381-90. doi: 10.1016/0005-7967(94)90001-9.
Reference Type
BACKGROUND
Beidel DC, Turner SM, Jacob RG, Cooley MR. Assessment of social phobia: Reliability of an impromptu speech task. Journal of Anxiety Disorders 3(3):149-158. 1989.
Reference Type
BACKGROUND
Deveney CM, McHugh RK, Tolin DF, Pollack MH, Otto MW. Combining D-cycloserine and exposure-based CBT for the anxiety disorders. Clin Neuropsychiatry 6(2):75-82. 2009.
Reference Type
BACKGROUND
Hofmann SG. Enhancing exposure-based therapy from a translational research perspective. Behav Res Ther. 2007 Sep;45(9):1987-2001. doi: 10.1016/j.brat.2007.06.006. Epub 2007 Jun 17.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ULTR000454
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Virtual Reality System for Anxiety and OCD
NCT03636022
COMPLETED
NA
Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder
NCT04977544
UNKNOWN
NA
Efficacy of Virtual Reality Exposure Therapy Scripts for Social Phobia
NCT04850989
COMPLETED
NA
Virtual Reality Exposure in Spider Phobia
NCT03208400
COMPLETED
NA
Smartphone-based Virtual Reality Exposure and Standard Relaxation Training for Anxiety on an Inpatient Psychiatric Unit
NCT05050123
TERMINATED
NA
D-Cycloserine Enhancement of Exposure in Social Phobia
NCT00633984
COMPLETED
PHASE4
Virtual Reality for AnxIety Disorders - Randomized Controlled Trial
NCT05302518
COMPLETED
NA
Social Anxiety Virtual Reality Study
NCT04288180
TERMINATED
Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder
NCT02066792
COMPLETED
EARLY_PHASE1
Using Smartphones to Enhance the Treatment of Childhood Anxiety
NCT02259036
COMPLETED
NA
Imagery Rescripting and Imaginal Exposure for Social Anxiety: Mechanisms and Outcomes in an Analog Sample
NCT04635904
UNKNOWN
NA
oVRcome - Self Guided Virtual Reality for Social Anxiety Disorder
NCT05576259
COMPLETED
NA
A Novel Computer-Based Therapy for Social Anxiety
NCT03240003
SUSPENDED
NA
Virtual Reality and Concept of Control in the Treatment of Acrophobia
NCT02020824
UNKNOWN
NA
D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD
NCT01172873
COMPLETED
NA
iExposure Intervention for Social Anxiety
NCT06409247
RECRUITING
NA
CBT Versus CBT With Virtual Reality Exposure for Social Anxiety Disorder and Agoraphobia
NCT03845101
UNKNOWN
NA
Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
NCT00515879
COMPLETED
PHASE3
D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights
NCT01037101
UNKNOWN
NA
Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD
NCT03476902
COMPLETED
NA
Augmentation Study of A Computerized Treatment for Social Anxiety Disorder
NCT02372019
COMPLETED
NA
One Session Virtual Reality During Ongoing Treatment for Anxiety: Feasibility in Children and Adolescents
NCT06338800
NOT_YET_RECRUITING
NA
VR Mind and VR Mind+ Intervention
NCT03895957
COMPLETED
NA
Efficacy of Targeted Memory Reactivation for Enhancing Exposure Therapy
NCT04663672
COMPLETED
NA
Computer - Based Treatment for Social Anxiety Disorder
NCT04663724
SUSPENDED
NA